(PRCT) Procept Biorobotics - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 1.487m USD | Total Return: -56.3% in 12m

Surgical Robots, Urology Devices, Medical Software
Total Rating 12
Safety 32
Buy Signal -0.44
Medical Devices
Industry Rotation: -0.4
Market Cap: 1.49B
Avg Turnover: 34.1M
Risk 3d forecast
Volatility55.0%
VaR 5th Pctl8.74%
VaR vs Median-3.49%
Reward TTM
Sharpe Ratio-1.19
Rel. Str. IBD9.7
Rel. Str. Peer Group18.4
Character TTM
Beta1.465
Beta Downside1.744
Hurst Exponent0.358
Drawdowns 3y
Max DD78.17%
CAGR/Max DD-0.10
CAGR/Mean DD-0.26
EPS (Earnings per Share) EPS (Earnings per Share) of PRCT over the last years for every Quarter: "2021-03": -2.6268, "2021-06": -0.41, "2021-09": -1.22, "2021-12": -0.42, "2022-03": -0.39, "2022-06": -0.43, "2022-09": -0.51, "2022-12": -0.56, "2023-03": -0.63, "2023-06": -0.56, "2023-09": -0.51, "2023-12": -0.54, "2024-03": -0.51, "2024-06": -0.5, "2024-09": -0.4, "2024-12": -0.35, "2025-03": -0.45, "2025-06": -0.35, "2025-09": -0.38, "2025-12": -0.53, "2026-03": -0.56,
EPS CAGR: -17.68%
EPS Trend: 36.2%
Last SUE: -2.57
Qual. Beats: -2
Revenue Revenue of PRCT over the last years for every Quarter: 2021-03: 7.192, 2021-06: 8.476, 2021-09: 8.668, 2021-12: 10.138, 2022-03: 14.197, 2022-06: 16.691, 2022-09: 20.349, 2022-12: 23.777, 2023-03: 24.404, 2023-06: 33.104, 2023-09: 35.102, 2023-12: 43.581, 2024-03: 44.539, 2024-06: 53.353, 2024-09: 58.37, 2024-12: 68.236, 2025-03: 69.162, 2025-06: 79.182, 2025-09: 83.327, 2025-12: 76.383, 2026-03: 83.132,
Rev. CAGR: 53.44%
Rev. Trend: 96.6%
Last SUE: 0.28
Qual. Beats: 0

Warnings

Interest Coverage Ratio -30.9 is critical

Altman Z'' -6.12 < 1.0 - financial distress zone

Tailwinds

No distinct edge detected

Description: PRCT Procept Biorobotics

PROCEPT BioRobotics Corporation is a surgical robotics firm specializing in minimally invasive urologic solutions, specifically for the treatment of benign prostatic hyperplasia (BPH). The company designs and manufactures the AquaBeam and HYDROS Robotic Systems, which utilize image-guided Aquablation therapy to address lower urinary tract symptoms in male patients.

Operating within the Health Care Equipment sector, the company utilizes a razor-and-blade business model where the initial sale of robotic consoles generates recurring revenue through the subsequent sale of single-use handpieces and service contracts. The urological robotics market is characterized by high barriers to entry due to stringent regulatory requirements and the clinical data necessary to shift standard-of-care surgical practices.

Investors may find ValueRays quantitative analysis useful for comparing this companys valuation against other medical technology peers.

Headlines to Watch Out For
  • Aquablation therapy adoption rates drive recurring revenue through high-margin disposable handpiece sales
  • Expansion of installed base for HYDROS and AquaBeam systems accelerates capital equipment growth
  • Favorable private payer coverage expansion increases patient access and procedure volume potential
  • High research and development spending delays profitability despite strong double-digit revenue growth
Piotroski VR‑10 (Strict) 2.0
Net Income: -102.5m TTM > 0 and > 6% of Revenue
FCF/TA: -0.17 > 0.02 and ΔFCF/TA 0.44 > 1.0
NWC/Revenue: 113.2% < 20% (prev 165.9%; Δ -52.75% < -1%)
CFO/TA -0.14 > 3% & CFO -70.1m > Net Income -102.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 6.73 > 1.5 & < 3
Outstanding Shares: last quarter (56.5m) vs 12m ago 2.90% < -2%
Gross Margin: 62.98% > 18% (prev 0.63%; Δ 6.24k% > 0.5%)
Asset Turnover: 63.99% > 50% (prev 47.97%; Δ 16.03% > 0%)
Interest Coverage Ratio: -30.92 > 6 (EBITDA TTM -102.4m / Interest Expense TTM 3.53m)
Altman Z'' -6.12
A: 0.75 (Total Current Assets 428.0m - Total Current Liabilities 63.6m) / Total Assets 487.1m
B: -1.38 (Retained Earnings -673.2m / Total Assets 487.1m)
C: -0.22 (EBIT TTM -109.0m / Avg Total Assets 503.2m)
D: -4.83 (Book Value of Equity -673.2m / Total Liabilities 139.4m)
Altman-Z'' Score: -6.12 = D
Beneish M -2.65
DSRI: 0.94 (Receivables 96.4m/79.3m, Revenue 322.0m/249.1m)
GMI: 1.00 (GM 62.98% / 62.71%)
AQI: 1.48 (AQ_t 0.02 / AQ_t-1 0.01)
SGI: 1.29 (Revenue 322.0m / 249.1m)
TATA: -0.07 (NI -102.5m - CFO -70.1m) / TA 487.1m)
Beneish M-Score: -2.65 (Cap -4..+1) = A
What is the price of PRCT shares? As of May 20, 2026, the stock is trading at USD 25.91 with a total of 1,291,920 shares traded.
Over the past week, the price has changed by -9.69%, over one month by +0.70%, over three months by -3.18% and over the past year by -56.30%.
Is PRCT a buy, sell or hold? Procept Biorobotics has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy PRCT.
  • StrongBuy: 6
  • Buy: 2
  • Hold: 2
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the PRCT price?
Analysts Target Price 30.4 17.5%
Procept Biorobotics (PRCT) - Fundamental Data Overview as of 19 May 2026
P/S = 4.6168
P/B = 4.1551
Revenue TTM = 322.0m USD
EBIT TTM = -109.0m USD
EBITDA TTM = -102.4m USD
Long Term Debt = 51.7m USD (from longTermDebt, last quarter)
 Short Term Debt = unknown (none)
 Debt = 51.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -194.0m USD (from netDebt column, last quarter)
Enterprise Value = 1.29b USD (1.49b + Debt 51.7m - CCE 245.6m)
Interest Coverage Ratio = -30.92 (Ebit TTM -109.0m / Interest Expense TTM 3.53m)
EV/FCF = -16.05x (Enterprise Value 1.29b / FCF TTM -80.6m)
FCF Yield = -6.23% (FCF TTM -80.6m / Enterprise Value 1.29b)
FCF Margin = -25.02% (FCF TTM -80.6m / Revenue TTM 322.0m)
Net Margin = -31.82% (Net Income TTM -102.5m / Revenue TTM 322.0m)
Gross Margin = 62.98% ((Revenue TTM 322.0m - Cost of Revenue TTM 119.2m) / Revenue TTM)
Gross Margin QoQ = 64.89% (prev 60.63%)
Tobins Q-Ratio = 2.65 (Enterprise Value 1.29b / Total Assets 487.1m)
Interest Expense / Debt = 1.58% (Interest Expense 818k / Debt 51.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -86.1m (EBIT -109.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.73 (Total Current Assets 428.0m / Total Current Liabilities 63.6m)
Debt / Equity = 0.15 (Debt 51.7m / totalStockholderEquity, last quarter 347.7m)
 Debt / EBITDA = 1.89 (negative EBITDA) (Net Debt -194.0m / EBITDA -102.4m)
 Debt / FCF = 2.41 (negative FCF - burning cash) (Net Debt -194.0m / FCF TTM -80.6m)
 Total Stockholder Equity = 369.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -20.36% (Net Income -102.5m / Total Assets 487.1m)
RoE = -27.70% (Net Income TTM -102.5m / Total Stockholder Equity 369.9m)
RoCE = -25.86% (EBIT -109.0m / Capital Employed (Equity 369.9m + L.T.Debt 51.7m))
 RoIC = -20.43% (negative operating profit) (NOPAT -86.1m / Invested Capital 421.5m)
 WACC = 10.81% (E(1.49b)/V(1.54b) * Re(11.14%) + D(51.7m)/V(1.54b) * Rd(1.58%) * (1-Tc(0.21)))
Discount Rate = 11.14% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 5.04%
 [DCF] Fair Price = unknown (Cash Flow -80.6m)
 EPS Correlation: 36.17 | EPS CAGR: -17.68% | SUE: -2.57 | # QB: -2
Revenue Correlation: 96.63 | Revenue CAGR: 53.44% | SUE: 0.28 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.46 | Chg30d=-11.76% | Revisions=-33% | Analysts=10
EPS next Quarter (2026-09-30): EPS=-0.34 | Chg30d=+3.45% | Revisions=+0% | Analysts=10
EPS current Year (2026-12-31): EPS=-1.52 | Chg30d=+1.75% | Revisions=+0% | GrowthEPS=+11.9% | GrowthRev=+29.5%
EPS next Year (2027-12-31): EPS=-0.87 | Chg30d=+1.93% | Revisions=+0% | GrowthEPS=+42.9% | GrowthRev=+23.2%
[Analyst] Revisions Ratio: -33%